BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Average Price Target of $35.00 According to Analysts

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $35.00.

A number of brokerages have recently weighed in on BLSM. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of BlossomHill Therapeutics in a research note on Wednesday, September 30th. Wall Street Zen upgraded shares of BlossomHill Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price for the company.

BlossomHill Therapeutics Price Performance

BLSM opened at $15.76 on Wednesday. BlossomHill Therapeutics has a twelve month low of $12.93 and a twelve month high of $27.99. The business’s 50-day moving average price is $19.03.

BlossomHill Therapeutics (NASDAQ:BLSM) last announced its quarterly earnings data on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). As a group, analysts anticipate that BlossomHill Therapeutics will post -5.54 EPS for the current fiscal year.

Insider Buying and Selling

In other BlossomHill Therapeutics news, Director John P. Schmid acquired 6,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the transaction, the director directly owned 6,000 shares in the company, valued at $96,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc acquired 625,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.